Selected High-Risk Patients With Upper Tract Urothelial Carcinoma Treated With Radical Nephroureterectomy for Adjuvant Chemotherapy: A Multi-Institutional Retrospective Study

被引:15
|
作者
Ikeda, Masaomi [1 ,2 ]
Matsumoto, Kazumasa [1 ]
Hirayama, Takahiro [1 ]
Koguchi, Dai [3 ]
Murakami, Yasukiyo [4 ]
Matsuda, Daisuke [5 ]
Okuno, Norihiko [6 ]
Utsunomiya, Takuji [4 ]
Taoka, Yoshinori [3 ]
Irie, Akira [2 ]
Iwamura, Masatsugu [1 ]
机构
[1] Kitasato Univ, Sch Med, Dept Urol, Sagamihara, Kanagawa, Japan
[2] Kitasato Univ, Kitasato Inst Hosp, Dept Urol, Tokyo, Japan
[3] Kitasato Univ, Med Ctr, Dept Urol, Saitama, Japan
[4] Sagamihara Kyodo Hosp, Kanagawa Prefectural Federat Agr Cooperat Hlth &, Dept Urol, Sagamihara, Kanagawa, Japan
[5] Higashiyamato Hosp, Dept Urol, Tokyo, Japan
[6] Natl Hosp Org Sagamihara Hosp, Dept Urol, Sagamihara, Kanagawa, Japan
关键词
Lymph node status; Lymphovascular invasion; pT stage; Surgical margin; Tumor grade; UPPER URINARY-TRACT; TRANSITIONAL-CELL CARCINOMA; BLADDER-CANCER; MICROSATELLITE INSTABILITY; TUMORS; OUTCOMES;
D O I
10.1016/j.clgc.2017.10.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We investigated the efficacy of adjuvant chemotherapy (AC) in patients with upper tract urothelial carcinoma (UTUC) and determined those who qualified for AC. In multivariate analyses, 5 factors (>= pT3, pN+, G3, lymphovascular invasion, positive surgical margin) were independently predictive of poorer survival. Having more than 3 risk factors defined the high-risk group. AC was associated with improved survival in high-risk UTUC. Background: No definitive evidence exists regarding use of adjuvant chemotherapy (AC) for high-risk cases after radical nephroureterectomy (RNU), and the benefit of AC remains controversial. The aims of this study were to evaluate the efficacy of AC in patients with upper tract urothelial carcinoma (UTUC) and to determine those who qualified for AC. Patients and Methods: From 1990 to 2015, 449 patients with nonmetastatic UTUC underwent RNU at 6 Kitasato University-affiliated hospitals. Eight patients who received neoadjuvant chemotherapy were excluded from this study. One hundred patients (23%) received platinum-based AC for a median of 3 courses. Disease-free survival and cancer-specific survival (CSS) were estimated using the Kaplan-Meier method. Multivariate analyses were performed with the Cox proportional hazards regression model, controlling for the effects of clinicopathological factors. Results: The median age was 69 years, and the median follow-up period was 35.7 months. In multivariate analyses, factors independently predictive of poorer survival included pT stage (>= pT3), lymph node status (pN+), tumor grade (Grade 3), lymphovascular invasion, and soft tissue surgical margin. For the risk stratification model, patients were categorized into 3 groups on the basis of these 5 risk factors. In the high-risk group (at least 3 risk factors, 83 patients), 41 patients (49%) were treated with AC, and the 5-year CSS rate was higher in the AC group compared with the non-AC group (P = .02). Conclusion: Having more than 3 risk factors defined the high-risk group among UTUC patients after RNU. AC was associated with improved CSS in patients with high-risk UTUC. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:E669 / E675
页数:7
相关论文
共 50 条
  • [21] The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study
    Lucca, Ilaria
    Kassouf, Wassim
    Kapoor, Anil
    Fairey, Adrian
    Rendon, Ricardo A.
    Izawa, Jonathan I.
    Black, Peter C.
    Fajkovic, Harun
    Seitz, Christian
    Remzi, Mesut
    Nyirady, Peter
    Roupret, Morgan
    Margulis, Vitaly
    Lotan, Yair
    de Martino, Michela
    Hofbauer, Sebastian L.
    Karakiewicz, Pierre I.
    Briganti, Alberto
    Novara, Giacomo
    Shariat, Shahrokh F.
    Klatte, Tobias
    BJU INTERNATIONAL, 2015, 116 (01) : 72 - 78
  • [22] The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study
    Tanaka, Nobuyuki
    Kikuchi, Eiji
    Kanao, Kent
    Matsumoto, Kazuhiro
    Shirotake, Suguru
    Kobayashi, Hiroaki
    Miyazaki, Yasumasa
    Ide, Hiroki
    Obata, Jun
    Hoshino, Katsura
    Hayakawa, Nozomi
    Kosaka, Takeo
    Oyama, Masafumi
    Miyajima, Akira
    Momma, Tetsuo
    Nakagawa, Ken
    Jinzaki, Masahiro
    Nakajima, Yosuke
    Oya, Mototsugu
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 48.e19 - 48.e26
  • [23] Quality indicators for the management of high-risk upper tract urothelial carcinoma requiring radical nephroureterectomy
    Koenig, Frederik
    Shariat, Shahrokh F.
    Karakiewicz, Pierre, I
    Mun, Dong-Ho
    Rink, Michael
    Pradere, Benjamin
    CURRENT OPINION IN UROLOGY, 2021, 31 (04) : 291 - 296
  • [24] THE PREDICTIVE VALUE OF C-REACTIVE PROTEIN FOR PROGNOSIS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH CISPLATIN-BASED CHEMOTHERAPY FOLLOWING RADICAL NEPHROURETERECTOMY: MULTI-INSTITUTIONAL STUDY
    Obata, Jun
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Shirotake, Suguru
    Matsumoto, Kazuhiro
    Oyama, Masahumi
    Kanao, Kent
    Kobayashi, Hiroaki
    Miyazaki, Yasumasa
    Ide, Hiroki
    Ishioka, Katsura
    Miyajima, Akira
    Momma, Tetsuo
    Nakagawa, Ken
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2014, 191 (04): : E919 - E919
  • [25] MULTI-INSTITUTIONAL ANALYSIS OF RENAL FUNCTION OUTCOMES FOLLOWING RADICAL NEPHROURETERECTOMY AND PARTIAL URETERECTOMY FOR UPPER TRACT UROTHELIAL CARCINOMA
    Singla, Nirmish
    Bagrodia, Aditya
    Gayed, Bishoy
    Palazzi, Kerrin
    Mirheydar, Hossein
    Harrow, Brian
    Jacobs, Corbin
    Youssef, Ramy
    Darwish, Oussama
    Sagalowsky, Arthur
    Lotan, Yair
    Derweesh, Ithaar
    Margulis, Vitaly
    JOURNAL OF UROLOGY, 2014, 191 (04): : E316 - E316
  • [26] Multi-institutional analysis of renal function outcomes following radical nephroureterectomy and partial ureterectomy for upper tract urothelial carcinoma
    Singla, Nirmish
    Gayed, Bishoy A.
    Bagrodia, Aditya
    Krabbe, Laura-Maria
    Palazzi, Kerrin L.
    Mirheydar, Hossein
    Harrow, Brian
    Jacobs, Corbin
    Youssef, Ramy
    Darwish, Oussama
    Sagalowsky, Arthur
    Lotan, Yair
    Derweesh, Ithaar
    Margulis, Vitaly
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2015, 33 (06) : 268.e1 - 268.e7
  • [27] Effectiveness of tislelizumab combined with chemotherapy for high recurrence risk patients with upper tract urothelial carcinoma after radical nephroureterectomy
    Zhang, J.
    Chen, Z.
    Zhu, H.
    ANNALS OF ONCOLOGY, 2024, 35 : S1524 - S1524
  • [28] IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY
    Miyazaki, Yasumasa
    Kikuchi, Eiji
    Tanaka, Nobuyuki
    Shirotake, Suguru
    Matsumoto, Kazuhiro
    Kobayashi, Hiroaki
    Ide, Hiroki
    Obata, Jun
    Ishioka, Katsura
    Kosaka, Takeo
    Kanao, Kent
    Oyama, Masafumi
    Miyajima, Akira
    Momma, Tetsuo
    Hasegawa, Shintaro
    Nakajima, Yosuke
    Jinzaki, Masahiro
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2016, 195 (04): : E369 - E370
  • [29] NEOADJUVANT CHEMOTHERAPY PRIOR TO RADICAL NEPHROURETERECTOMY IN PATIENTS WITH ADVANCED UPPER TRACT UROTHELIAL CARCINOMA
    Tollefson, Matthew
    Quevedo, J. Fernando
    Trost, Landon
    Chow, George
    Blute, Michael
    JOURNAL OF UROLOGY, 2010, 183 (04): : E168 - E168